On Invalid Date, Corvus Pharmaceuticals (NASDAQ: CRVS) reported Q4 2023 earnings per share (EPS) of -$0.13, up 38.1% year over year. Total Corvus Pharmaceuticals earnings for the quarter were -$6.65 million. In the same quarter last year, Corvus Pharmaceuticals's earnings per share (EPS) was -$0.21.
As of Q2 2024, Corvus Pharmaceuticals's earnings has grown year over year. Corvus Pharmaceuticals's earnings in the past year totalled -$27.03 million.
What is CRVS's earnings date?
Corvus Pharmaceuticals's earnings date is Invalid Date. Add CRVS to your watchlist to be reminded of CRVS's next earnings announcement.
What was CRVS's revenue last quarter?
On Invalid Date, Corvus Pharmaceuticals (NASDAQ: CRVS) reported Q4 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Corvus Pharmaceuticals's revenue was $0.00.
What was CRVS's revenue growth in the past year?
As of Q2 2024, Corvus Pharmaceuticals's revenue has grown null year over year. Corvus Pharmaceuticals's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.